Detalles de la búsqueda
1.
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States.
Invest New Drugs
; 41(6): 851-860, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37796398
2.
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Invest New Drugs
; 41(3): 421-430, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37074571
3.
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
Future Oncol
; 17(24): 3151-3162, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33993740
4.
Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes.
Drug Metab Dispos
; 47(5): 453-464, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30787101
5.
In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity.
Drug Metab Dispos
; 44(10): 1682-91, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27504016
6.
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Nature
; 465(7294): 96-100, 2010 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-20410884
7.
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
J Infect Dis
; 206(7): 1002-11, 2012 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22896665
8.
Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
Cancer Chemother Pharmacol
; 89(5): 629-641, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35366072
9.
Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer.
Clin Pharmacokinet
; 59(9): 1135-1148, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338345
10.
Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model.
Clin Pharmacokinet
; 59(9): 1149-1160, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338346
11.
Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects.
Clin Pharmacokinet
; 59(2): 229-244, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31432469
12.
Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Clin Cancer Res
; 26(14): 3517-3524, 2020 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32366670
13.
Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 26(17): 4460-4467, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32561663
14.
An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer.
Cancer Chemother Pharmacol
; 82(3): 457-468, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29974203
15.
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
J Clin Invest
; 128(8): 3333-3340, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29939161
16.
Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing.
Cancer Chemother Pharmacol
; 75(1): 49-58, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25344090
17.
Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.
Clin Pharmacol Drug Dev
; 4(1): 63-73, 2015 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27128004
18.
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma.
Clin Cancer Res
; 21(8): 1843-50, 2015 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25628399
19.
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
J Rheumatol
; 42(10): 1752-60, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26233509
20.
Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.
J Clin Pharmacol
; 55(12): 1406-14, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26096139